Uptravi (selexipag) is a small molecule pharmaceutical. Selexipag was first approved as Uptravi on 2015-12-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. It is known to target prostacyclin receptor. Uptravi's patents are valid until 2036-12-01 (FDA).